Format

Send to

Choose Destination
J Allergy Clin Immunol. 2012 Sep;130(3):563-71. doi: 10.1016/j.jaci.2012.07.027.

Novel targeted therapies for eosinophilic disorders.

Author information

1
Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. mikewechsler@gmail.com

Abstract

Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approvedĀ for other disorders.

PMID:
22935585
PMCID:
PMC3625625
DOI:
10.1016/j.jaci.2012.07.027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center